TSXV:NVH - Post Discussion
Post by
Aberta1 on Aug 17, 2018 9:31am
HEART OF THE PROBLEM – KEVIN COSTA, CSO
https://www.futuretechpodcast.com/podcasts/heart-problem-kevin-costa-cso-scientific-co-founder-novoheart-stem-cells-tissue-engineering-challenge-defeat-human-heart-conditions-diseases/ Novoheart’s primary goal is to innovate and impact drug discovery and the evolution of heart therapeutics with their proprietary bioengineered human heart constructs, to advance them further, into transplantable grafts for cell-based regenerative heart therapies with significantly improved safety as well as efficacy. By growing pieces of tissues that can emulate certain aspects of the human heart, Novoheart can perform laboratory testing to better understand how drugs and therapeutics might interact with a human heart. Costa explains how 90% of drugs ultimately fail and never make it to clinics to help patients, even after a decade of work with several billion dollars spent on research. He discusses how animal testing is perhaps the primary reason for drug failures in development, for animal testing is not exceptionally predictive of how a particular drug will work in a human body. And for fear of potentially extreme cardiac side effects, human testing is rarely if ever done; thus, Novoheart’s testing on their laboratory-produced human tissues allows for more reliable testing that will be indicative of the actual human use of a drug.
Be the first to comment on this post